JUNB and supranuclear palsy, progressive, 1: We performed immunofluorescence labeling of those candidates’ gene products in postmortem PSP and CBD samples (i.e., MFG) to validate JUNB and TFEB network dysregulation though their predicted target genes (Fig. 7a, b).